TKPHF - Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript
Takeda Pharmaceutical Co Ltd (TAK) Q2 2021 Earnings Conference Call October 29, 2020, 05:30 ET Company Participants Christopher O'Reilly - IR Christophe Weber - President, CEO & Representative Director Andrew Plump - President, Research & Development and Director Constantine Saroukos - CFO & Director Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants Fumiyoshi Sakai - Crédit Suisse Hidemaru Yamaguchi - Citigroup Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley Akinori Ueda - Goldman Sachs Group Presentation Operator Good day, everyone, and welcome to the conference call of Takeda Pharmaceutical Company Limited. [Operator Instructions]. Now we start the conference. Mr. O'Reilly, please go ahead. Christopher O'Reilly Thank you very much for your participation in the conference call for the financial results of FY '20 second quarter of Takeda Pharmaceutical Company Limited. I'm Christopher O'Reilly, Global Head of Investor Relations. Before starting, I'd like to remind everyone
For further details see:
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript